160 related articles for article (PubMed ID: 22777926)
1. Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
Wachter D; Kallenberg K; Wrede A; Schulz-Schaeffer W; Behm T; Rohde V
J Neurol Surg A Cent Eur Neurosurg; 2012 Nov; 73(6):401-6. PubMed ID: 22777926
[TBL] [Abstract][Full Text] [Related]
2. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
4. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients.
Stummer W; Novotny A; Stepp H; Goetz C; Bise K; Reulen HJ
J Neurosurg; 2000 Dec; 93(6):1003-13. PubMed ID: 11117842
[TBL] [Abstract][Full Text] [Related]
6. Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping.
Schucht P; Beck J; Abu-Isa J; Andereggen L; Murek M; Seidel K; Stieglitz L; Raabe A
Neurosurgery; 2012 Nov; 71(5):927-35; discussion 935-6. PubMed ID: 22895402
[TBL] [Abstract][Full Text] [Related]
7. 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy.
Kamp MA; Felsberg J; Sadat H; Kuzibaev J; Steiger HJ; Rapp M; Reifenberger G; Dibué M; Sabel M
Acta Neurochir (Wien); 2015 Feb; 157(2):207-13; discussion 213-4. PubMed ID: 25547719
[TBL] [Abstract][Full Text] [Related]
8. 5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma.
Schucht P; Knittel S; Slotboom J; Seidel K; Murek M; Jilch A; Raabe A; Beck J
Acta Neurochir (Wien); 2014 Feb; 156(2):305-12; discussion 312. PubMed ID: 24449075
[TBL] [Abstract][Full Text] [Related]
9. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
Lomax AJ; Hill PA; Ashley DM
J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery.
Aldave G; Tejada S; Pay E; Marigil M; Bejarano B; Idoate MA; Díez-Valle R
Neurosurgery; 2013 Jun; 72(6):915-20; discussion 920-1. PubMed ID: 23685503
[TBL] [Abstract][Full Text] [Related]
12. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study.
da Silva EB; Vasquez MWM; de Almeida Teixeira BC; Neto MC; Sprenger F; Filho JLN; Almeida-Lopes L; Ramina R
Acta Neurochir (Wien); 2024 May; 166(1):212. PubMed ID: 38739282
[TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery.
Senft C; Seifert V; Hermann E; Franz K; Gasser T
Neurosurgery; 2008 Oct; 63(4 Suppl 2):257-66; discussion 266-7. PubMed ID: 18981831
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ventricular wall fluorescence during 5-aminolevulinic-guided surgery for glioblastoma.
Tejada-Solís S; Aldave-Orzaiz G; Pay-Valverde E; Marigil-Sánchez M; Idoate-Gastearena MA; Díez-Valle R
Acta Neurochir (Wien); 2012 Nov; 154(11):1997-2002; discussion 2002. PubMed ID: 22930281
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
19. [Surgery of high-grade gliomas guided by fluorescence: a retrospective study of 22 patients].
Jacquesson T; Ducray F; Maucort-Boulch D; Armoiry X; Louis-Tisserand G; Mbaye M; Pelissou-Guyotat I; Guyotat J
Neurochirurgie; 2013 Feb; 59(1):9-16. PubMed ID: 23318102
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence-guided resection of primary and recurrent malignant gliomas with 5-aminolevulinic acid. Preliminary results.
Tykocki T; Michalik R; Bonicki W; Nauman P
Neurol Neurochir Pol; 2012; 46(1):47-51. PubMed ID: 22426762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
